<table>
<thead>
<tr>
<th>Number</th>
<th>Reference Number</th>
<th>Name of Trial</th>
<th>Target Date To Recruit</th>
<th>Date Agreed to recruit target number of patients</th>
<th>Total Number Of Patients Recruited At The Agreed Target Date</th>
<th>Number Of Patients Agreed</th>
<th>Number Of Patients Agreed (Enter Same In Both if Only One)</th>
<th>Minimum Number Of Patients Agreed</th>
<th>Maximum Number Of Patients Agreed</th>
<th>Reason For Closure Of Trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>14/EM/0091</td>
<td>137994</td>
<td>A phase III, randomized, open label, multicenter, controlled trial of vinorelbine versus physician's choice in previously-treated, HER2 negative, gemline BRCA mutation-positive breast cancer patients.</td>
<td>Number Agreed</td>
<td>4</td>
<td>4</td>
<td>Date Agreed</td>
<td>31/10/2015</td>
<td>7</td>
<td>29/03/2017</td>
<td>Withdrawn By Sponsor</td>
</tr>
<tr>
<td>15/NW/0713</td>
<td>171836</td>
<td>A phase II, open label, multicentric, randomized, parallel design study investigating the efficacy and safety of GTX-024 on metastatic or locally advanced ER+ / HER2- breast cancer (BC) in postmenopausal women.</td>
<td>Number Agreed</td>
<td>5</td>
<td>5</td>
<td>Not Available / Not Agreed</td>
<td></td>
<td>20</td>
<td>17/02/2017</td>
<td>Recruitment Finished</td>
</tr>
<tr>
<td>15/LO/1990</td>
<td>185316</td>
<td>A randomized open-label phase III study of single agent Pembrolizumab versus single agent chemotherapy per physician's choice for metastatic triple negative breast cancer (mTNBC) – KEYNOTE-119</td>
<td>Number Agreed</td>
<td>4</td>
<td>4</td>
<td>Date Agreed</td>
<td>31/12/2017</td>
<td>11</td>
<td>16/03/2017</td>
<td>Recruitment Finished</td>
</tr>
<tr>
<td>15/LO/0834</td>
<td>172183</td>
<td>W029522 (Impassion-130)</td>
<td>Number Agreed</td>
<td>6</td>
<td>6</td>
<td>Date Agreed</td>
<td>31/07/2017</td>
<td>3</td>
<td>05/06/2017</td>
<td>Withdrawn By Sponsor</td>
</tr>
<tr>
<td>16/EM/0320</td>
<td>208246</td>
<td>A randomized, multicenter, double-blind, placebo-controlled phase II study of the efficacy and safety of TRA1ZU-051 in combination with Atezolizumab or ATEZOLIZUMAB-placebo in patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab and taxane-based therapy.</td>
<td>Number Agreed</td>
<td>2</td>
<td>2</td>
<td>Date Agreed</td>
<td>30/06/2016</td>
<td>3</td>
<td>28/07/2017</td>
<td>Recruitment Finished</td>
</tr>
<tr>
<td>13/JO/1083</td>
<td>131703</td>
<td>A multicenter, open-label, phase I Ib Study of MNL0128 (an Oral mTORC1/2 Inhibitor) in combination With MNL1117 (an oral PI3K inhibitor) in adult patients with advanced, nonhematologic malignancies (Enter Same In Minimum Number)</td>
<td>Number Agreed</td>
<td>4</td>
<td>4</td>
<td>Not Available / Not Agreed</td>
<td></td>
<td>11</td>
<td>01/10/2016</td>
<td>Recruitment Finished</td>
</tr>
<tr>
<td>14/JO/0444</td>
<td>139567</td>
<td>A phase I, open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2666212 in subjects with relapsed/refractory diffuse large B cell and transformed follicular lymphoma.</td>
<td>Number Agreed</td>
<td>25</td>
<td>25</td>
<td>Date Agreed</td>
<td>01/03/2015</td>
<td>2</td>
<td>19/06/2016</td>
<td>Withdrawn By Sponsor</td>
</tr>
<tr>
<td>14/JO/2024</td>
<td>164984</td>
<td>A Phase 1, First-in-Human Study of Escalating Doses of Oral TVB-2640 in Patients with Solid Tumours</td>
<td>Number Agreed</td>
<td>10</td>
<td>10</td>
<td>Date Agreed</td>
<td>01/07/2016</td>
<td>8</td>
<td>02/11/2016</td>
<td>Withdrawn By Sponsor</td>
</tr>
<tr>
<td>16/ES/0004</td>
<td>192492</td>
<td>D081X00001 (MED101A) Advanced Solid Tumours</td>
<td>Number Agreed</td>
<td>5</td>
<td>5</td>
<td>Date Agreed</td>
<td>30/06/2017</td>
<td>5</td>
<td>29/05/2017</td>
<td>Recruitment Finished</td>
</tr>
<tr>
<td>16/JO/0397</td>
<td>191752</td>
<td>A phase I, open-label, dose escalation and expansion study of Demcizumab Plus Pembrolizumab and Demcizumab plus Pembrolizumab, Pembrolizumab and Carboplatin in Patients with Locally Advanced or Metastatic Solid Tumours</td>
<td>Number Agreed</td>
<td>10</td>
<td>10</td>
<td>Date Agreed</td>
<td>31/02/2017</td>
<td>5</td>
<td>10/04/2017</td>
<td>Withdrawn By Sponsor</td>
</tr>
<tr>
<td>13/LO/1616</td>
<td>137039</td>
<td>Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MED4736 in Subjects with Advanced Solid Tumours</td>
<td>Number Agreed</td>
<td>5</td>
<td>5</td>
<td>Date Agreed</td>
<td>30/06/2015</td>
<td>5</td>
<td>30/10/2016</td>
<td>Recruitment Finished</td>
</tr>
<tr>
<td>14/SQ/095</td>
<td>154130</td>
<td>PIK3CA - Evaluation of an immunomodulatory maintenance treatment in patients with metastatic colorectal cancer who have demonstrated clinical activity of GSK2666212 as a single agent (Enter Same In Minimum Number)</td>
<td>Number Agreed</td>
<td>10</td>
<td>10</td>
<td>Date Agreed</td>
<td>01/10/2019</td>
<td>23</td>
<td>11/05/2017</td>
<td>Recruitment Finished</td>
</tr>
<tr>
<td>14/JO/2119</td>
<td>160335</td>
<td>Phase II randomized, double blind, placebo controlled clinical trial of BB808 plus weekly paclitaxel vs placebo plus weekly paclitaxel in adult patients with advanced, previously treated gastric and gastro-esophageal junction adenocarcinoma</td>
<td>Number Agreed</td>
<td>12</td>
<td>12</td>
<td>Date Agreed</td>
<td>27/03/2017</td>
<td>18</td>
<td>01/12/2016</td>
<td>Recruitment Finished</td>
</tr>
<tr>
<td>15/LQ/1246</td>
<td>180129</td>
<td>CA906E</td>
<td>Number Agreed</td>
<td>6</td>
<td>6</td>
<td>Not Available / Not Agreed</td>
<td></td>
<td>3</td>
<td>05/05/2017</td>
<td>Recruitment Finished</td>
</tr>
</tbody>
</table>
15/EE/0333 187464 A randomized, multicenter, acute-to-mono, placebo-controlled, Phase 2/3 study of the Bruton’s Tyrosine Kinase inhibitor BTK in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma

Range Agreed

8 12 Date Agreed 01/04/2017 8 29/03/2017 9 Recruitment Finished

16/GO/0334 193988 Recruitments

16/W5/0248 186331 A Phase III Double-blind, Placebo Controlled Study of XelodaTM in Metastatic Colon Cancer

Range Agreed

1 3 Date Agreed 31/10/2016 7 02/11/2016 7 Recruitment Finished

16/CO/0676 200558 MK-8628 Haematologic Malignancy Trial

Number Agreed

3 3 Date Agreed 29/06/2017 3 16/12/2016 3 Recruitment Finished

16/NW/0379 200426 Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Navelirin plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer

Number Agreed

6 6 Date Agreed 31/05/2017 1 28/07/2017 2 Recruitment Finished

16/SC/0351 205155 A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Range Agreed

1 4 Date Agreed 31/12/2017 10 10/04/2017 14 Recruitment Finished

16/EM/0408 211983 A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin-5 Fluorouracil versus Placebo-Cisplatin-5 Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Range Agreed

1 5 Date Agreed 30/04/2019 0 03/05/2017 0 Recruitment Finished

16/CO/1784 211244 A Novel Phase I/IIa Open-label Study of JPM-101 in Combination with Selected Standard of Care (SOC) Regimens in Patients with Metastatic or Unresectable Cancer at Study Entry

Range Agreed

1 40 Date Agreed 31/03/2019 0 31/07/2017 0 Withdrawn By Sponsor

15/SC/0354 129260 A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma

Number Agreed

4 4 Date Agreed 01/01/2015 4 21/10/2016 9 Recruitment Finished

16/NE/0027 187317 Javelin Ovarian 200 BNP10009

Number Agreed

6 6 Date Agreed 30/06/2017 15 19/04/2017 15 Recruitment Finished

14/EM/0130 140751 A Phase III Open-label, Randomized, Partially blinded Study of IMMN-002 (WAY-1006352) in combination with Seprafine in subjects with highly pretreated, post- or neo-adjuvant, solid tumors with a documented Human Epidermal Growth Factor Receptor-2 (HER-2) positive, receptor-positive tumor

Number Agreed

5 5 Date Agreed 29/06/2015 10 01/09/2017 11 Recruitment Finished

14/NW/1358 158383 A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELNIOREX (JPT330) VERSUS SPECIFIED PHYSICIAN'S CHOICE IN PATIENTS ≥ 60 YEARS OLD WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY AND/OR TRANSPLANTATION

Number Agreed

1 1 Date Agreed 29/02/2016 1 02/12/2016 1 Recruitment Finished

15/HY/0434 185622 A Phase 2b/3 Study of Dostarlimab in patients with advanced colorectal cancer

Number Agreed

3 3 Date Agreed 30/04/2017 0 20/02/2017 0 Withdrawn By Host

13/NE/0323 137956 STORM - A Phase 1, Dose-Finding and Signal-Seeking Study of the Safety and Efficacy of irinotecan and chemotherapy in patients with metastatic colorectal cancer

Number Agreed

8 8 Date Agreed 30/11/2015 7 05/01/2017 6 Withdrawn By Sponsor

15/EM/0546 194511 MBE04736 in or in combo with Tremelimumab vs SOC in 1st line SCCHN cancer

Number Agreed

3 3 Date Agreed 16/05/2017 14 01/03/2017 14 Recruitment Finished

16/CO/1133 203679 KEYNOTE 046 - A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Range Agreed

6 11 Date Agreed 22/12/2016 11 12/04/2017 12 Recruitment Finished
An Open-Label, Randomized Phase 3 Trial of Nivolumab and Nivolumab plus Ipilimumab versus Platinum Doublet Chemotherapy in Patients with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)  
Number Agreed: 6  
Date Agreed: 31/08/2019  
Withdrawn By: Sponsor

CheckMate 451: CHECKpoint pathway and nivolumab  
Clinical Trial Evaluation 451  
Number Agreed: 4  
Date Agreed: 14/10/2017  
Recruitment Finished

A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment after Induction with Nab-Paclitaxel plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)  
Number Agreed: 6  
Date Agreed: 02/06/2017  
Withdrawn By: Sponsor

A Phase 3 Multicenter Open-label Study of Brigatinib versus Crizotinib  
Range Agreed: 1-3  
Date Agreed: 28/07/2017  
Recruitment Finished

A Randomized Phase 3 Open Label Study of Nivolumab plus Ipilimumab versus Platinum Doublet Chemotherapy in Patients with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)  
Number Agreed: 6  
Date Agreed: 08/09/2017  
Withdrawn By: Sponsor

A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory Malignant Mesothelioma with BAP1 Loss of Function  
Number Agreed: 6  
Date Agreed: 18/05/2017  
Recruitment Finished

A Phase 1-2 Study of Onapristone in Patients with Advanced Castration-resistant Prostate Cancer  
Number Agreed: 25  
Date Agreed: 31/01/2017  
Withdrawn By: Sponsor

PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer  
Number Agreed: 25  
Date Agreed: 14/04/2017  
Withdrawn By: Sponsor

A Phase 1-2 Study of Onapristone in Patients with Advanced Castration-resistant Prostate Cancer  
Number Agreed: 25  
Date Agreed: 31/12/2015  
Recruitment Finished

A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone  
Number Agreed: 20  
Date Agreed: 14/10/2016  
Withdrawn By: Sponsor

CheckMate 511: CHECKpoint pathway and nivolumab  
Clinical Trial Evaluation 511  
Range Agreed: 3-5  
Date Agreed: 20/01/2017  
Withdrawn By: Sponsor

A Phase 3 Double Blind Randomised Study of Orally Administered PLX3397 in Patients with Advanced Solid Tumours  
Number Agreed: 5  
Date Agreed: 24/02/2017  
Withdrawn By: Sponsor

Evaluation of avelumab combined with axitinib in advanced RCC  
Number Agreed: 5  
Date Agreed: 03/10/2016  
Recruitment Finished

A Phase 1B, Open Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib (AG-013736) in Combination with Crizotinib (PF-02341066) in Patients with Advanced Solid Tumors  
Number Agreed: 5  
Date Agreed: 24/02/2017  
Recruitment Finished